LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) shares saw strong trading volume on Wednesday . 119,272 shares traded hands during mid-day trading, a decline of 18% from the previous session's volume of 144,909 shares.The stock last traded at $23.30 and had previously closed at $22.97.
LENZ Therapeutics Price Performance
The business has a 50 day moving average of $24.23 and a 200 day moving average of $27.01.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of LENZ Therapeutics by 5.3% in the fourth quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company's stock valued at $34,022,000 after purchasing an additional 59,630 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of LENZ Therapeutics by 83.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock valued at $23,760,000 after purchasing an additional 374,326 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new position in shares of LENZ Therapeutics in the fourth quarter valued at $22,243,000. State Street Corp raised its stake in shares of LENZ Therapeutics by 18.7% in the third quarter. State Street Corp now owns 289,154 shares of the company's stock valued at $6,865,000 after purchasing an additional 45,600 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its stake in LENZ Therapeutics by 16.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company's stock worth $4,103,000 after acquiring an additional 20,000 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
